FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116831767> ?p ?o ?g. }

• W2116831767 endingPage "1736" @default.
• W2116831767 startingPage "1726" @default.
• W2116831767 abstract "The goals and objectives of phase 1 clinical trials are changing to include further evaluation of endpoints such as molecular targeted effects, in addition to dose-toxicity profile of the investigational agent. Because of these changes in focus, the National Cancer Institute and Investigational Drug Steering Committee's Task Force on Clinical Trial Design met to evaluate the most efficient ways to design and implement early clinical trials with novel therapeutics. Clinical approaches discussed included the conventional 3 + 3 cohort expansion phase 1 design, multi-institutional phase 1 studies, accelerated titration designs, continual reassessment methods, the study of specific target patient populations, and phase 0 studies. Each of these approaches uniquely contributes to some aspect of the phase 1 study, with all focused on dose and schedule determination, patient safety, and limited patient exposure to ineffective doses of investigational agent. The benefit of labor-intensive generation of preliminary biomarker evidence of target inhibition, as well as the value of molecular profiling of the study population, is considered. New drug development is expensive and the failure rate remains high. By identifying patient populations expected to respond to the study agent and tailoring the treatment with a novel drug, investigators will be one step closer to personalizing cancer treatment. The fail early and fast approach is acceptable if the appropriate patient population is evaluated in the phase 1 trial. The approaches outlined in this overview address the merits, advantages, disadvantages, and obstacles encountered during first in human studies." @default.
• W2116831767 created "2016-06-24" @default.
• W2116831767 creator A5000204204 @default.
• W2116831767 creator A5029296725 @default.
• W2116831767 creator A5033078993 @default.
• W2116831767 creator A5080736692 @default.
• W2116831767 date "2010-03-14" @default.
• W2116831767 modified "2023-10-03" @default.
• W2116831767 title "Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee" @default.
• W2116831767 cites W1544350038 @default.
• W2116831767 cites W157796586 @default.
• W2116831767 cites W1895993106 @default.
• W2116831767 cites W1963773346 @default.
• W2116831767 cites W1965431780 @default.
• W2116831767 cites W1985995033 @default.
• W2116831767 cites W1992346046 @default.
• W2116831767 cites W2006990152 @default.
• W2116831767 cites W2007276247 @default.
• W2116831767 cites W2029409133 @default.
• W2116831767 cites W2038725811 @default.
• W2116831767 cites W2043911652 @default.
• W2116831767 cites W2045985885 @default.
• W2116831767 cites W2069317340 @default.
• W2116831767 cites W2073516247 @default.
• W2116831767 cites W2076108528 @default.
• W2116831767 cites W2076809452 @default.
• W2116831767 cites W2078274740 @default.
• W2116831767 cites W2103105040 @default.
• W2116831767 cites W2118342205 @default.
• W2116831767 cites W2118682535 @default.
• W2116831767 cites W2119597015 @default.
• W2116831767 cites W2124456142 @default.
• W2116831767 cites W2128373232 @default.
• W2116831767 cites W2132209219 @default.
• W2116831767 cites W2133954805 @default.
• W2116831767 cites W2137998467 @default.
• W2116831767 cites W2140081776 @default.
• W2116831767 cites W2141086589 @default.
• W2116831767 cites W2144216228 @default.
• W2116831767 cites W2149344761 @default.
• W2116831767 cites W2149626936 @default.
• W2116831767 cites W2158740848 @default.
• W2116831767 cites W2165524738 @default.
• W2116831767 cites W2167228337 @default.
• W2116831767 cites W2171608750 @default.
• W2116831767 cites W2312270541 @default.
• W2116831767 cites W2414966294 @default.
• W2116831767 cites W4245400734 @default.
• W2116831767 cites W91108901 @default.
• W2116831767 doi "https://doi.org/10.1158/1078-0432.ccr-09-1961" @default.
• W2116831767 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5207802" @default.
• W2116831767 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20215542" @default.
• W2116831767 hasPublicationYear "2010" @default.
• W2116831767 type Work @default.
• W2116831767 sameAs 2116831767 @default.
• W2116831767 citedByCount "148" @default.
• W2116831767 countsByYear W21168317672012 @default.
• W2116831767 countsByYear W21168317672013 @default.
• W2116831767 countsByYear W21168317672014 @default.
• W2116831767 countsByYear W21168317672015 @default.
• W2116831767 countsByYear W21168317672016 @default.
• W2116831767 countsByYear W21168317672017 @default.
• W2116831767 countsByYear W21168317672018 @default.
• W2116831767 countsByYear W21168317672019 @default.
• W2116831767 countsByYear W21168317672020 @default.
• W2116831767 countsByYear W21168317672021 @default.
• W2116831767 countsByYear W21168317672022 @default.
• W2116831767 countsByYear W21168317672023 @default.
• W2116831767 crossrefType "journal-article" @default.
• W2116831767 hasAuthorship W2116831767A5000204204 @default.
• W2116831767 hasAuthorship W2116831767A5029296725 @default.
• W2116831767 hasAuthorship W2116831767A5033078993 @default.
• W2116831767 hasAuthorship W2116831767A5080736692 @default.
• W2116831767 hasBestOaLocation W21168317671 @default.
• W2116831767 hasConcept C126322002 @default.
• W2116831767 hasConcept C143998085 @default.
• W2116831767 hasConcept C148482608 @default.
• W2116831767 hasConcept C160735492 @default.
• W2116831767 hasConcept C162324750 @default.
• W2116831767 hasConcept C177713679 @default.
• W2116831767 hasConcept C19527891 @default.
• W2116831767 hasConcept C2779328685 @default.
• W2116831767 hasConcept C2780035454 @default.
• W2116831767 hasConcept C2908647359 @default.
• W2116831767 hasConcept C2910824759 @default.
• W2116831767 hasConcept C31760486 @default.
• W2116831767 hasConcept C50522688 @default.
• W2116831767 hasConcept C535046627 @default.
• W2116831767 hasConcept C64903051 @default.
• W2116831767 hasConcept C71924100 @default.
• W2116831767 hasConcept C98274493 @default.
• W2116831767 hasConcept C99454951 @default.
• W2116831767 hasConceptScore W2116831767C126322002 @default.
• W2116831767 hasConceptScore W2116831767C143998085 @default.
• W2116831767 hasConceptScore W2116831767C148482608 @default.
• W2116831767 hasConceptScore W2116831767C160735492 @default.
• W2116831767 hasConceptScore W2116831767C162324750 @default.
• W2116831767 hasConceptScore W2116831767C177713679 @default.

• next